otitis%20media%20-%20acute
OTITIS MEDIA - ACUTE
Otitis media is a general term used to describe inflammation of the middle ear which may be caused by an acute infection.
The symptoms are usually nonspecific and include otalgia (pulling of ear in an infant), irritability, otorrhea with or without fever.
Symptoms of upper respiratory tract infection may also be present.

Pharmacotherapy

Symptomatic Therapy

Analgesics

  • Eg Paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs) [eg Ibuprofen]
    • Opioids may occasionally be indicated
  • Considered the mainstay of pain relief for acute otitis media (AOM)
  • Effective analgesia for mild-moderate pain

Antibiotic Therapy

  • There are no data regarding initially withholding antimicrobial therapy in adult patients w/ AOM
    • Treatment prevents development of complications

Amoxicillin/High-dose Amoxicillin

  • Amoxicillin at sufficient doses is still considered the 1st-line agent for AOM
  • It is effective against most of the bacteria which cause AOM including susceptible & intermediate-resistant pneumococci
  • In areas where Penicillin-resistant pneumococci are common, high-dose Amoxicillin should be given

Amoxicillin/clavulanic Acid (High dose)

  • High doses of Amoxicillin combined w/ clavulanic acid are recommended for patients who fail standard Amoxicillin therapy or in those who present w/ severe illness
  • This combination will provide coverage for beta-lactamase-producing organisms (eg H influenzae & M catarrhalis along w/ Penicillin-resistant S pneumoniae)

Cephalosporins (2nd & 3rd Generation)

  • Cefdinir, Cefpodoxime, Cefprozil & Cefuroxime are the preferred agents because of their effectiveness against drug-resistant S pneumoniae, H influenzae & M catarrhalis
    • These agents may be considered in patients w/ non-type 1 hypersensitivity reaction to Penicillin
  • Ceftriaxone [intravenous (IV)/intramuscular (IM)] may be considered in patients unable to take oral medications (eg vomiting)
    • Also recommended x 3 days in patients who fail Amoxicillin/clavulanate
    • Has superior efficacy to S pneumoniae compared w/ alternative oral antibiotics

Co-trimoxazole

  • Co-trimoxazole may be considered in patients w/ type 1 allergy to Penicillin
  • Use may be limited by local resistance patterns

Erythromycin/sulfafurazole

  • May be considered in patients w/ type 1 allergy to Penicillin
  • Depending on local resistance patterns, may be preferred over Co-trimoxazole

Advanced Macrolides

  • Eg Azithromycin or Clarithromycin
  • Active against the major pathogens that cause AOM
  • These agents have decreased activity against drug-resistant S pneumoniae

Clindamycin

  • May be considered in a patient who has persistent AOM after previous complete antibiotic therapy & in whom tympanocentesis is not possible for Gram stain & culture
  • Clindamycin may be effective against Penicillin-resistant pneumococcal infection not responding to other treatment
  • Clindamycin is not active against H influenzae or M catarrhalis & should not be used if these are suspected

Duration of Antibiotic Therapy

  • Optimal duration of antimicrobial therapy in AOM patients is uncertain
    • May continue antibiotics x 5-7 days in mild-moderate illness & up to 10 days if severe
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
3 days ago
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

5 days ago
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.